Literature DB >> 31413792

PROTACs and Targeted Protein Degradation for Treating ALK-Mediated Cancers.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2019        PMID： 31413792      PMCID： PMC6691478          DOI： 10.1021/acsmedchemlett.9b00296

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

1.  Crizotinib Versus Chemotherapy on ALK-positive NSCLC: A Systematic Review of Efficacy and Safety.

Authors:  Mingxia Wang; Guanqi Wang; Haiyan Ma; Baoen Shan
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

Review 2.  Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives.

Authors:  Zhifa Cao; Qian Gao; Meixian Fu; Nan Ni; Yuting Pei; Wen-Bin Ou
Journal:  Oncol Lett       Date:  2018-12-20       Impact factor: 2.967

Review 3.  ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer.

Authors:  Gina Rosas; Rossana Ruiz; Jhajaira M Araujo; Joseph A Pinto; Luis Mas
Journal:  Crit Rev Oncol Hematol       Date:  2019-02-16       Impact factor: 6.312
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.